Robeco Institutional Asset Management B.V. bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 40,600 shares of the company’s stock, valued at approximately $3,492,000. Robeco Institutional Asset Management B.V. owned about 0.10% of Omnicell as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in Omnicell during the fourth quarter valued at approximately $409,000. Legal & General Group Plc boosted its position in shares of Omnicell by 0.8% in the fourth quarter. Legal & General Group Plc now owns 92,921 shares of the company’s stock worth $5,669,000 after purchasing an additional 695 shares during the period. Millennium Management LLC boosted its position in shares of Omnicell by 182.1% in the fourth quarter. Millennium Management LLC now owns 25,354 shares of the company’s stock worth $1,553,000 after purchasing an additional 56,254 shares during the period. Amalgamated Bank bought a new position in shares of Omnicell in the fourth quarter worth approximately $373,000. Finally, Norges Bank bought a new position in shares of Omnicell in the fourth quarter worth approximately $12,125,000. 97.37% of the stock is currently owned by institutional investors.
Omnicell stock traded down $1.13 during mid-day trading on Wednesday, reaching $68.49. 31,011 shares of the company’s stock traded hands, compared to its average volume of 683,229. Omnicell, Inc. has a 12-month low of $56.96 and a 12-month high of $92.59. The stock has a market capitalization of $2.94 billion, a P/E ratio of 44.76, a price-to-earnings-growth ratio of 2.32 and a beta of 1.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.54 and a current ratio of 2.03. The firm’s 50 day moving average price is $78.69.
In other Omnicell news, EVP Dan S. Johnston sold 9,929 shares of the stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $85.47, for a total transaction of $848,631.63. Following the transaction, the executive vice president now directly owns 31,505 shares in the company, valued at approximately $2,692,732.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Randall A. Lipps sold 5,000 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $70.30, for a total transaction of $351,500.00. Following the transaction, the chairman now owns 140,506 shares in the company, valued at $9,877,571.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,375 shares of company stock worth $3,291,918. Company insiders own 2.77% of the company’s stock.
A number of equities analysts have weighed in on OMCL shares. Benchmark upped their price target on shares of Omnicell from $82.00 to $90.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. BidaskClub lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th. Craig Hallum upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Friday, July 26th. TheStreet lowered shares of Omnicell from a “b” rating to a “c+” rating in a research report on Thursday, April 25th. Finally, Zacks Investment Research upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $79.11.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.